We begin the countdown of this year’s IAM Market Makers list, which names the elite individuals who drive global patent dealmaking and value creation from their positions inside corporates, NPEs, investment institutions and other entities. Today, positions 40 to 31.
Despite forecasts of a sharp rise in pharma deal-making activity, it has proved to be a slow year on the M&A front. One reason may be that licensing partnerships are proving far more popular than many had expected.
Proposed limits on royalty payments would be even stricter than those scrapped in 2009 liberalisation of FDI policies. Impact would be felt by global brand and technology giants with listed subsidiaries in India.
New start-up Operem hopes to launch IP exchange by year's end after closing series A funding round in April. CEO Tim Londergan says the project can lure financial investors into the IP world.
There will be no changes to the $3 to $15 per car royalty fees licensees are asked to pay to access the patents that form the Avanci auto patent platform, the firm has told IAM. “As we add new patent owners to the Avanci platform, the price the…
It would appear that the recipient of the largest ever IP-backed loan has come full circle to cautionary tale.
Tranlin Paper, based in China’s Shandong Province, borrowed well over a billion dollars from the China Development bank in 2014 on the… Read more
In this month’s round-up of life sciences-related patent news, we report on the year’s first pharma mega-merger, the latest developments in a must-watch CRISPR-Cas9 patent dispute, calls from Novartis’ CEO for reform to the US biosimilar patent… Read more
The US Supreme Court’s treatment of patentability in recent times has often been frustrating to life sciences innovators, with last month’s refusal to grasp the nettle of patent eligible subject matter in Cleveland Clinic Foundation v True Health… Read more
Twitter found itself on the wrong end of an infringement lawsuit late last month when an entity called Digi Portal accused the social media company of infringing on one of its patents.
According to a recent RPX newsletter, Digi Portal is an… Read more
After two years of uncertainty and no little gloom, a recent Federal Circuit decision may just herald the long-awaited swing-back in the pendulum that software patent owners in the United States have been waiting for. Some, though, still believe that Congress must bite the bullet and take a look at Section 101
The UK vote to leave the European Union may have surprised and disappointed many in the IP community, but a rush to bypass the decision and implement the unitary patent package would be a mistake Read more